Aetiology of hepatocellular carcinoma and response to immunotherapy: is the problem inherent in the classification of non-viral disease?

F. Tovoli,R. Chen,C. Vivaldi,P. Federico,A. Palloni,L.A. Natola,C. Soldà,B. Stefanini,I. Garajova,L. Ielasi,S. De Lorenzo,A. Granito,G. Monaco,G. Masi,S. Lonardi,G. Brandi,B. Daniele,A. Dalbeni,L. Lani,G. Svegliati-Baroni,C. Campani,F. Piscaglia,ARTE study group

DOI: https://doi.org/10.1016/j.dld.2024.01.162

IF: 5.165

2024-02-01

Digestive and Liver Disease

Abstract:Introduction Preclinical studies and post-hoc analyses of randomized clinical trials hint at a possible impaired efficacy of immune checkpoint inhibitors in patients with non-viral hepatocellular carcinoma (HCC) in general and metabolic dysfunction-associated steatotic liver disease (MASLD) in specific. The heterogeneity of non-viral aetiologies and the possibility of multiple concurrent aetiologies may justify seemingly discordant data. Aim To explore and compare the objective response rate [ORR], disease control rate [DCR], progression-free survival [PFS], and overall survival [OS] of HCC patients treated with atezolizumab/bevacizumab (AB), stratified according to different criteria for non-viral etiologies and MASLD. Methods The ARTE database (March 2022-November 2023) prospectively enrolled patients treated with AB in a real-life setting. Three different classifications of HCC aetiologies were explored: 1) viral vs non-viral; 2) MASLD (either single-etiology or combined with other etiologies, for instance, HCV) vs non-MASLD; 3) single-etiology MASLD (sMASLD) vs non-sMASLD. ORR, DCR, PFS and OS comparisons were performed using univariable analyses and multivariable models, including other predictors of outcome. Results Data of 157 patients from 12 centres were collected. The ORR, DCR, median PFS and OS in the study population were 19.7%, 62.4%, 19.8 (95% CI 15.8-23.8) and 10.5 months (6.3-14.7), respectively. Stratification according to the viral vs non-viral etiologies did not capture differences in the main outcome measures (Figure). Conversely, patients with sMASLD had shorter PFS and a trend toward a lower DCR than controls but without differences in OS. Conclusions Viral and non-viral aetiologies had no significant differences in their response to AB. Patients with sMASLD had a shorter PFS than controls, but this difference did not translate into impaired survival. Based on current evidence, aetiology alone should not preclude patients from receiving immune-oncology drugs. A longer follow-up might help understand possible confounding effects from second-line therapies on the interpretation of OS.

gastroenterology & hepatology